Top

Cancer Immunology, Immunotherapy

Published in:

01-05-2004 | Original Article

Characteristics of the killing mechanism of human natural killer cells against hepatocellular carcinoma cell lines HepG2 and Hep3B

Authors: Hyoung-Ran Kim, Hyun-Joo Park, Jeon Han Park, Se Jong Kim, Kunhong Kim, Jongsun Kim

Published in: Cancer Immunology, Immunotherapy | Issue 5/2004

Abstract

Purpose

Unlike normal hepatocytes, most hepatocellular carcinomas (HCCs) are quite resistant to death receptor-mediated apoptosis when the cell surface death receptor is cross linked with either agonistic antibodies or soluble death ligand proteins in vitro. The resistance might play an essential role in the escape from the host immune surveillance; however, it has not been directly demonstrated that HCCs are actually resistant to natural killer (NK) cell-mediated death. Therefore, this study investigated the molecular mechanism of NK cell-mediated cytotoxicity against the HCCs, HepG2, and Hep3B, using two distinct cytotoxic assays: a 4-h ⁵¹Cr-release assay and a 2-h [³H] thymidine release assay which selectively measures the extent of necrotic and apoptotic target cell death, respectively.

Methods

Most of the target cells exhibited marked morphologic changes when they were co-incubated with the NK cells, and the NK cytotoxicity against these HCCs was comparable to that against K562, a NK-sensitive leukemia cell line, when the cytotoxicity was assessed by a 4-h ⁵¹Cr release assay.

Results

The NK cells also induced significant apoptotic cell death in the Hep3B targets, but not in the HepG2 targets, when the cytotoxicity was assessed by a 2-h [³H]-thymidine release assay. In agreement with these results, procaspase-3 was activated in the Hep3B targets, but not in the HepG2 targets. Interestingly, mildly fixed NK cells had no detectable activity in the 4-h ⁵¹Cr release assay against both HepG2 and Hep3B targets, while they were similarly effective as the untreated NK cells in the 2-h [³H]-thymidine release assay, suggesting that the level of apoptotic cell death of the Hep3B targets is granule independent and might be primarily mediated by the death ligands of the NK cells.

Conclusion

This study found that a tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor interaction is involved in the NK cell-mediated apoptotic death of the Hep3B targets, but a Fas/Fas ligand (FasL) interaction is not.

Arase H, Arase N, Saito T (1995) Fas-mediated cytotoxicity by freshly isolated natural killer cells. J Exp Med 181:1235PubMed

Ashkenazi A, Dixit VM (1998) Death receptors: signaling and modulation. Science 281:1305CrossRefPubMed

Chuang W, Liu HW, Chang WY (1990) Natural killer cell activity in patients with hepatocellular carcinoma relative to early development and tumor invasion. Cancer 65:926PubMed

Duke RC, Chervenak R, Cohen JJ (1983) Endogenous endonuclease-induced DNA fragmentation: an early event in cell-mediated cytolysis. Proc Natl Acad Sci USA 80:6361PubMed

Earnshaw WC, Martins LM, Kaufmann SH (1999) Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 68:383PubMed

Feldmann G (1997) Liver Apoptosis. J Hepatol 26:1CrossRef

Fernandes-Alnemri T, Litwack G, Alnemri ES (1994) CPP32: a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem 269:30761PubMed

Galle PR, Hofmann WJ, Walczak H, Schller H, Otto G, Stremmel W, Krammer PH, Runkel L (1995) Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 182:1223PubMed

Galle PR, Krammer PH (1998) CD95-induced apoptosis in human liver disease. Semin Liver Dis 18:141PubMed

10.

Gorelik E, Rosen B, Copeland D, Weatherly B, Herberman RB (1984) Evaluation of the role of natural killer cells in radiation-induced leukemogenesis in mice. J Natl Cancer Inst 72:1397

11.

Higaki K, Yano H, Kojiro M (1996) Fas antigen expression and its relationship with apoptosis in human hepatocellular carcinoma and noncancerous tissues. Am J Pathol 149:429PubMed

12.

Hirofuji H, Kakumu S, Fiji A, Ohtani Y, Murase K, Tahara H (1987) Natural killer and activated killer activities in chronic liver disease and hepatocellular carcinoma: evidence for a decreased lymphokine induced activity of effector cells. Clin Exp Immunol 68:348PubMed

13.

Holcik M, Gibson H, Korneluk RG (2001) XIAP: apoptotic brake and promissing therapeutic target. Apoptosis 6:253CrossRefPubMed

14.

Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J (1997) Inhibition of death receptor signals by cellular FLIP. Nature 388:190PubMed

15.

Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, Strom SC (2000) Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6:564PubMed

16.

Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ, Podack ER, Zinkernagel RM, Hengartner H (1994) Cytotoxicity mediated by T-cells and natural killer cells is greatly impaired in perforin deficient mice. Nature 369:31PubMed

17.

Kashii Y, Giorda R, Herberman RB, Whiteside TL, Vujanovic NL (1999) Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J Immunol 163:5358PubMed

18.

Kayagaki N, Yamaguchi N, Nakayama M, Takeda K, Akiba H, Tsutsui H, Okamura H, Nakanishi K, Okumura K, Yagita H (1999) Expression and function of TNF-related apoptosis-inducing ligand on murine activates NK cells. J Immunol 163:1906PubMed

19.

Kim YS, Schwabe RF, Qian T, Lemasters JJ, Brenner DA (2002) TRAIL-mediated apoptosis requires NF-kB inhibition and the mitochondrial permeability transition in human hepatoma cells. Hepatology 36:1498CrossRefPubMed

20.

Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S (1997) Essential roles of the Fas ligand in the development of hepatitis. Nat Med 3:409PubMed

21.

Kurt-Jones EA, Beller DI, Mizel SB, Unanue ER (1985) Identification of a membrane associated interleukin 1 in macrophages. Proc Natl Acad Sci USA 82:1204PubMed

22.

Lamboley C, Bringuier AF, Camus E, Lardeux B, Groyer A, Feldmann G (2002) Overexpression of the mouse Fas gene in human Hep3B hepatoma cells overcomes their resistance to Fas-mediated apoptosis. J Hepatol 36:385CrossRefPubMed

23.

Lee RK, Spielman J, Zhao DY, Olsen KJ, Podack ER (1996) Perfolin, Fas ligand, and tumor necrosis factor are the major cytototoxic molecules used by lymphokine-activated killer cells. J Immunol 157:1919PubMed

24.

Leibson PJ (1997) Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity 6:655PubMed

25.

Lowin B, Beermann F, Schmidt A, Tschopp J (1994) A null mutation in the perforin gene impairs cytolytic T lymphocyte- and natural killer cell-mediated cytotoxicity. Proc Natl Acad Sci USA 91:11571PubMed

26.

Matzinger P (1991) The JAM test: a simple assay for DNA fragmentation and cell death. J Immunol Methods 145:185PubMed

27.

Medema JP, de Jong J, Peltenburg LTC, Verdegaal EME, Gorter A, Bres SA, Franken KLMC, Hahne M, Albar JP, Melief CJM, Offringa R (2001) Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci USA 98:11515CrossRefPubMed

28.

Montel AH, Bochan MR, Hobbs JA, Lynch DH, Brahmi Z (1995) Fas involvement in cytotoxicity mediated by human NK cells. Cell Immunol 166:236CrossRefPubMed

29.

Nagao M, Nakajima Y, Hisanaga M, Kayagaki N, Kanehiro H, Aomatsu Y, Ko S, Yagita H, Yamada T, Okumura K, Nakano H (1999) The alteration of Fas receptor and ligand system in hepatocellular carcinomas: How do hepatoma cells escape from the host immune surveillance in vivo? Hepatology 30:413PubMed

30.

Nakajima T, Mizushima N, Kanai K (1987) Relationship between natural killer activity and development of hepatocellular carcinoma in patients with cirrhosis of the liver. Jpn J Clin Oncol 17:327PubMed

31.

Natoli G, Ianni G, Costanzo A, Petrillo GD de, Ilari I, Chrillo P, Balsano C, Levrero M (1995) Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene 11:1157PubMed

32.

Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, Munday NA, Raju SM, Smulson ME, Yamin TT, Yu VL, Miller D (1995) Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376:37PubMed

33.

Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S (1993) Lethal effect of the anti-Fas antibody in mice. Nature 364:806PubMed

34.

Oshmi Y, Oda S, Honda Y, Nagata S, Miyazaki S (1996) Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. J Immunol 157:2909PubMed

35.

Oshimi Y, Oshimi K, Miyazaki S (1996) Necrosis and apoptosis associated with distinct Ca²⁺ response patterns in target cells attacked by human natural killer cells. J Physiol 495:319PubMed

36.

Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271:12687PubMed

37.

Podack ER, Hengartner H, Lichtenheld MG (1991) A central role of perforin in cytolysis? Annu Rev Immunol 9:129PubMed

38.

Riccardi C, Barlozzari CT, Santoni A, Herberman RB, Cesarini C (1981) Transfer of cyclophosphamide-treated mice of natural killer cells and in vivo natural reactivity against tumors. J Immunol 126:1284PubMed

39.

Rodella L, Zamai L, Rezzani R, Artico M, Peri G, Falconi M, Facchini A, Pelusi G, Vitale M (2001) Interleukin 2 and interleukin 15 differentially predispose natural killer cells to apoptosis mediated by endothelial and tumour cells. Br J Haematol 115:442CrossRefPubMed

40.

Sato T, Irie S, Kitada S, Reed JC (1995) FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 268:411PubMed

41.

Screpanti V, Wallin RPA, Ljunggren HG, Grandien A (2001) A central role for death-receptor-mediated apoptosis in the rejection of tumors by NK cells. J Immunol 167:2068PubMed

42.

Shi L, Kraut RP, Aebersold R, Greenberg AH (1992) A natural killer cell granule protein that induces DNA fragmentation and apoptosis. J Exp Med 175:553PubMed

43.

Shin EC, Shin JS, Park JH, Kim JJ, Kim H, Kim S (1998) Expression of Fas-related genes in human hepatocellular carcinomas. Cancer Lett 134:155CrossRefPubMed

44.

Shin EC, Shin WC, Choi Y, Kim H, Park JH, Kim S (2001) Effect of interferon-γ on the susceptibility to Fas (CD95/APO-1)-mediated cell death in human hepatoma cells. Cancer Immunol Immunother 50:23CrossRefPubMed

45.

Shin EC, Seong YR, Kim CH, Kim H, Ahn YS, Kim K, Kim SJ, Hong SS, Park JH (2002) Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin. Exp Mol Med 34:114PubMed

46.

Smyth MJ, Trapani JA (1995) Granzymes: exogenous proteinases that induce target cell apoptosis. Immunol Today 16:202CrossRefPubMed

47.

Son K, Kew M, Rabson AR (1982) Depressed natural killer cell activity in patients with hepatocellular carcinoma. Cancer 50:2820PubMed

48.

Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H, Okumura K (2001) Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 7:94CrossRefPubMed

49.

Taketomi A, Shimada M, Shirabe K, Kajiyama K, Gion T, Sugimachi K (1998) Natural killer cell activity in patients with hepatocellular carcinoma: a new prognostic indicator after hepatectomy. Cancer 83:58CrossRefPubMed

50.

Trinchieri G (1989) Biology of natural killer cells. Adv Immunol 47:187PubMed

51.

Vujanovic NL, Nagashima S, Herberman RB, Whiteside TL (1996) Nonsecretory apoptotic killing by human NK cells. J Immunol 157:1117PubMed

52.

Wahlberg BJ, Burholt DR, Kornblith P, Richards TJ, Bruffsky A, Herberman RB, Vujanovic NL (2001) Measurement of NK activity by the microcytotoxicity assay (MCA): a new application for an old assay. J Immunol Methods 253:69CrossRefPubMed

53.

Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157CrossRefPubMed

54.

Walsh CM, Matloubian M, Liu CC, Ueda R, Kurahara CG, Christensen JL, Huang MT, Young JD, Ahmed R, Clark WR (1994) Immune function in mice lacking the perforin gene. Proc Natl Acad Sci USA 91:10854

55.

Whiteside TL, Herberman RB (1995) The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol 7:704CrossRefPubMed

56.

Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, Goodwin RG (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673PubMed

57.

Wiltrout RH, Herberman RB, Zhang SR, Chirigos MA, Ortaldo JR, Green KM, Talmadge JE (1985) Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver. J Immunol 134:4267PubMed

58.

Woo M, Hakem R, Soengas MS, Duncan GS, Shahinian A, Kagi D, Hakem A, McCurrach M, Khoo W, Kaufman SA, Senaldi G, Howard T, Lowe SW, Mak TW (1998) Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev 12:806PubMed

59.

Yagita H, Nakata M, Kawasaki A, Shinkai Y, Okumura K (1992) Role of perforin in lymphocyte-mediated cytolysis. Adv Immunol 51:215PubMed

60.

Yamanaka T, Shiraki K, Sugimoto K, Ito T, Fujikawa K, Ito M, Takase K, Moriyama M, Nakano T, Suzuki A (2000) Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 32:482PubMed

61.

Young JD (1989) Killing of target cells by lymphocytes: a mechanistic view. Physiol Rev 69:250PubMed

62.

Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B (1998) NK-cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med 188:2375CrossRefPubMed

63.

Zychlinsky A, Zheng LM, Liu CC, Young JD (1991) Cytolytic lymphocytes induce both apoptosis and necrosis in target cells. J Immunol 146:393PubMed

Title: Characteristics of the killing mechanism of human natural killer cells against hepatocellular carcinoma cell lines HepG2 and Hep3B
Authors: Hyoung-Ran Kim
Hyun-Joo Park
Jeon Han Park
Se Jong Kim
Kunhong Kim
Jongsun Kim
Publication date: 01-05-2004
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 5/2004
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-003-0461-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2004

Identification of a MHC class-II restricted epitope in carcinoembryonic antigen

Further development of local IL-2 therapy of cancer: multiple versus single IL-2 treatment of transplanted murine colon carcinoma

Trials and tribulations of immunotherapy as a treatment option for patients with squamous cell carcinoma of the head and neck

Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA

British Society for Immunology annual congress, Harrogate, UK, 2–5 December 2003

Effect of albumin fusion on the biodistribution of interleukin-2

Keynote webinar | Spotlight on antibody–drug conjugates in cancer